GlassScriptPhysician profile
Patricia Davidson
NPI 1497829196
$10,905.46
in general payments reported to CMS, 2019-2025
20 companies · $990 in 2025
The $990 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,690 · 2020: $2,825 · 2021: $264 · 2022: $360 · 2023: $250 · 2024: $1,526 · 2025: $990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,105 · Travel and Lodging: $654 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,104.63 |
| Travel and Lodging | $653.61 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,843.20 | 2019-2023 | Freestyle Libre 3 |
| Boston Scientific Corporation | $1,178.53 | 2020-2025 | Watchman Access System, Bodyguardian, Watchman |
| Novo Nordisk INC | $1,030.33 | 2019-2025 | Wegovy, Ozempic |
| Pfizer INC. | $641.67 | 2019-2025 | |
| Amgen INC. | $622.67 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $340.19 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $272.50 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $204.41 | 2019-2022 | |
| Esperion Therapeutics, INC. | $139.23 | 2024-2025 | Nexletol, Nexlizet |
| Bridgebio Pharma, INC. | $117.28 | 2025 | Attruby |
| Merck Sharp & Dohme LLC | $113.95 | 2019-2024 | Verquvo |
| Kowa Pharmaceuticals America, INC. | $73.34 | 2019 | |
| Sanofi-Aventis U.S. LLC | $63.52 | 2019 | |
| Amarin Pharma, INC. | $54.52 | 2019-2020 | |
| Atricure, INC. | $49.19 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $48.41 | 2023-2024 | Camzyos |
| Lilly USA, LLC | $44.61 | 2019-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $30.62 | 2025 | |
| Abbvie INC. | $26.29 | 2025 | |
| Arbor Pharmaceuticals, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.